In addition to the question of how to classify the latest test results on benzoyl peroxide (BPO) preparations used in acne treatment, the results of clinical studies on bimekizumab and new drug candidates such as vilobelimab and LAD191 in hidradenitis suppurativa (HS) were presented.
Dieser Inhalt ist nur für Benutzer der Gruppe: Medizinische Fachperson zugänglich
Jetzt beitreten
Jetzt beitreten
Already a member? Log in here
